Joseph Jordan
Neurocritical Care · Tucson, AZNPI 1033261557
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,828 of the $45,652 with a category attached, or 98.2%. GSK accounts for 63.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $38,520 and has fallen 86.6% since, to $5,170 in 2025.
Across 118 payments — averaging $386.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$29K
- Sanofi US Services Inc.$10K
- E.r. Squibb & Sons, L.L.C.$5K
- AstraZeneca$2K
- Acadia Pharmaceuticals Inc$181
- Jazz Pharmaceuticals Inc.$150
- plus $440 from 9 others
Across 160 payments — averaging $1401.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$203K
- Eli Lilly$21K
What the payments were for
- Consulting fees$44,82898%
- Food & beverage$8242%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 30 | $28,840 |
| Sanofi US Services Inc. | 36 | $9,680 |
| E.r. Squibb & Sons, L.L.C. | 4 | $4,583 |
| AstraZeneca(2 entities) | 4 | $1,779 |
| Acadia Pharmaceuticals Inc | 11 | $181 |
| Jazz Pharmaceuticals Inc. | 8 | $150 |
| Otsuka America Pharmaceutical, Inc. | 6 | $98 |
| UCB, Inc. | 3 | $81 |
| Pfizer | 4 | $63 |
| Biogen | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $56 |
| Novartis | 2 | $37 |
| Eisai Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $14 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAR439954$7,285
- EFPEGLENATIDE$1,485
How this compares
Too few neurocritical care providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurocritical care in Tucson
- Firas KaddouhTucson$2K
- Yazeed AlolayanTucson$35
- Ruchira JhaPhoenix$6K
- Brian AppavuPhoenix$4K
- Victor ZachPhoenix$1K
- Rachel ThomasPhoenix$517
- Fiona LynchPhoenix$279
- Nassim MatinPhoenix$244
- Daniella SisniegaPhoenix$238
- Aditya KumarPhoenix$140
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.